Amgen Inc. (NASDAQ: AMGN) filings indicate recent movement in the holdings of one of its top executives. Nancy A. Grygiel, the company's Senior Vice President and Chief Compliance Officer, executed two distinct transactions involving common stock during the first week of May 2026.
On May 4, 2026, Ms. Grygiel sold 1,237 shares of Amgen common stock. The transaction was completed at an average price of $323.7272 per share, which brought the total value of the sale to approximately $400,450. This reported figure represents an average execution price for the volume of shares sold.
Prior to this sale, on May 2, 2026, Ms. Grygiel disposed of 242 shares of the company's common stock. These specific shares were valued at $329.82 per share and were utilized to satisfy tax withholding obligations, amounting to roughly $79,816.
Following these two transactions, Ms. Grygiel maintains a direct ownership stake of 7,009 shares in Amgen common stock. This direct holding is supplemented by 72 Dividend Equivalents, which are linked to her unvested Restricted Stock Units and are distributed as shares of common stock according to the established vesting schedule. Additionally, she holds an indirect interest consisting of 106.1864 shares through the company's 401(k) Plan.
Key Market Observations
Insider Activity in Biotechnology: The transactions by a Chief Compliance Officer provide specific data points regarding executive liquidity and compensation management within the large-cap biotech sector.
Strong Financial Performance: Amgen's recent first-quarter 2026 financial results demonstrated significant strength. The company reported earnings per share (EPS) of $5.15, which surpassed the forecasted amount of $4.80 by a margin of 7.29%. Furthermore, revenue for the quarter reached $8.62 billion, exceeding the anticipated $8.59 billion.
Dividend Consistency: The company continues to demonstrate long-term shareholder returns, having raised its dividend for 15 consecutive years. The current dividend yield stands at 3.06%.
Risks and Uncertainties
Market Volatility Post-Earnings: Despite surpassing EPS and revenue expectations for the first quarter of 2026, Amgen's stock saw a decline during after-hours trading sessions. This highlights the uncertainty in how the market prices high-performing biotech stocks relative to guidance and broader economic sentiment.
Valuation Divergence: While the stock has seen a 26% increase over the past year and is currently trading at $329.59, there remains a distinction between market price and perceived value. Analysis suggests that while the stock has performed well, the biotech giant may remain undervalued at current levels.